WESTFORD, Mass., Nov. 11, 2013 /PRNewswire/ -- Cynosure, Inc.
(NASDAQ: CYNO), which develops and markets laser- and light-based
aesthetic treatment systems for high-volume applications, today
announced that Chairman, Chief Executive Officer and President
Michael Davin and Executive Vice
President, Chief Operating Officer and Chief Financial Officer
Timothy Baker will be presenting at
two upcoming investor conferences.
- On Thursday, November 14 at
10:30 a.m. (ET), management will
present at the Canaccord Genuity Medical Technology &
Diagnostics Forum in New York
City.
- On Tuesday, November 19 at
9:05 a.m. (ET), management will
participate in a fireside chat at the Barclays Select Growth
Conference in New York City.
To access the live or archived webcasts of these events, visit
the "Investor Relations" portion of Cynosure's website,
www.cynosure.com.
About Cynosure, Inc.
Cynosure develops and markets
aesthetic treatment systems that enable plastic surgeons,
dermatologists and other medical practitioners to perform
non-invasive and minimally invasive procedures to remove hair,
treat vascular and benign pigmented lesions, remove multi-colored
tattoos, revitalize the skin, liquefy and remove unwanted fat
through laser lipolysis, reduce cellulite, treat toe fungus and
ablate sweat glands. Cynosure's product portfolio is composed
of a broad range of energy sources including Alexandrite, diode,
Nd: YAG, picosecond, pulse dye, and Q-switched lasers and intense
pulsed light. Cynosure sells its products globally
under the Cynosure, Palomar and ConBio brand names through a direct
sales force in the United States,
Canada, Mexico, France, Germany, Spain, the United
Kingdom, Australia,
China, Japan and Korea, and through international
distributors in approximately 100 other countries. For
corporate or product information, visit Cynosure's website at
www.cynosure.com.
Contact:
Scott Solomon
Vice President
Sharon Merrill
617.542.5300
CYNO@investorrelations.com
SOURCE Cynosure, Inc.